In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Allogene Therapeutics Inc.

http://allogene.com/

Latest From Allogene Therapeutics Inc.

Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue

A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role. 

Clinical Trials Drug Safety

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

Financing ImmunoOncology

Allogene Takes Step Closer To Off-The-Shelf CAR-Ts

Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion. 

ASCO Clinical Trials

Is CAR-NK The Natural Successor To CAR-Ts?

There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.

Clinical Trials Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register